Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone609-275-0500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.47 billion
Profitability
Miscellaneous
Employees4,500
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable
Integra Lifesciences (NASDAQ:IART) Frequently Asked Questions
What is Integra Lifesciences' stock symbol?
Integra Lifesciences trades on the NASDAQ under the ticker symbol "IART."
When did Integra Lifesciences' stock split? How did Integra Lifesciences' stock split work?
Integra Lifesciences's stock split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly issued shares were distributed to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences stock prior to the split would have 200 shares after the split.
How were Integra Lifesciences' earnings last quarter?
Integra Lifesciences Holdings Corp (NASDAQ:IART) posted its quarterly earnings data on Wednesday, July, 24th. The life sciences company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.08. The life sciences company had revenue of $383.60 million for the quarter, compared to analyst estimates of $373.29 million. Integra Lifesciences had a return on equity of 16.30% and a net margin of 6.76%. The firm's revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.60 earnings per share. View Integra Lifesciences' Earnings History.
When is Integra Lifesciences' next earnings date?
What guidance has Integra Lifesciences issued on next quarter's earnings?
Integra Lifesciences updated its FY19 earnings guidance on Wednesday, July, 24th. The company provided earnings per share guidance of $2.70-2.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.70. The company issued revenue guidance of $1.515-1.525 billion, compared to the consensus revenue estimate of $1.52 billion.
What price target have analysts set for IART?
11 analysts have issued twelve-month target prices for Integra Lifesciences' stock. Their predictions range from $50.00 to $75.00. On average, they anticipate Integra Lifesciences' share price to reach $62.4545 in the next year. This suggests a possible upside of 2.3% from the stock's current price. View Analyst Price Targets for Integra Lifesciences.
What is the consensus analysts' recommendation for Integra Lifesciences?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra Lifesciences in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Integra Lifesciences.
What are Wall Street analysts saying about Integra Lifesciences stock?
Here are some recent quotes from research analysts about Integra Lifesciences stock:
- 1. According to Zacks Investment Research, "Integra LifeSciences exited the second quarter of 2019 on a strong note with better-than-expected results. Organic revenue growth was encouraging and was above the company’s expectation. Within global neurosurgery business, sales in dural access and repair increased in low-single digits on an organic basis with growth in both graft and sealant product lines. Benefiting from product launches and an enhanced sales force performance, the company envisions faster organic growth during the second half of 2019. On the flip side, escalating costs and expenses have been a major headwind for Integra Lifesciences. A tough competitive landscape adds to the woes. Overall, Integra LifeSciences outperformed its industry in the past three months." (9/2/2019)
- 2. Cantor Fitzgerald analysts commented, "We maintain our Neutral rating and 12-month price target of $50 on IART. Although we view IART’s long-range plan as impressive, we believe execution over the next few quarters is critical to restoring investor confidence in the stock. We think it is appropriate to stay on the sidelines at this time, but we might become more positive on the stock if the company were to execute on its integration and salesforce restructuring goals. We think IART is fairly valued at current levels, appropriately balancing the long-term opportunities with the risk of near-term disruption from the Codman acquisition and the changes to the OTT sales channel structure." (2/21/2019)
Has Integra Lifesciences been receiving favorable news coverage?
News coverage about IART stock has trended somewhat negative this week, InfoTrie reports. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Integra Lifesciences earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave news headlines about the life sciences company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Integra Lifesciences.
Are investors shorting Integra Lifesciences?
Integra Lifesciences saw a decrease in short interest in August. As of August 31st, there was short interest totalling 943,000 shares, a decrease of 18.9% from the July 31st total of 1,163,200 shares. Based on an average daily trading volume, of 433,200 shares, the short-interest ratio is presently 2.2 days. Currently, 1.3% of the company's stock are short sold. View Integra Lifesciences' Current Options Chain.
Who are some of Integra Lifesciences' key competitors?
Some companies that are related to Integra Lifesciences include ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Hill-Rom (HRC), Haemonetics (HAE), Penumbra (PEN), Globus Medical (GMED), Cantel Medical (CMD), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI) and Nevro (NVRO).
What other stocks do shareholders of Integra Lifesciences own?
Who are Integra Lifesciences' key executives?
Integra Lifesciences' management team includes the folowing people:
- Mr. Peter J. Arduini, Pres, CEO & Director (Age 54)
- Dr. Richard E. Caruso Ph.D., Founder and Chairman Emeritus (Age 76)
- Mr. Glenn G. Coleman, Corp. VP of International & CFO (Age 51)
- Mr. Daniel L. Reuvers, Corp. VP and Pres of Specialty Surgical Solutions (Age 56)
- Mr. Robert T. Davis Jr., Corp. VP and Pres of Orthopedics & Tissue Technologies (Age 60)
Who are Integra Lifesciences' major shareholders?
Integra Lifesciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.78%), BlackRock Inc. (7.78%), Vanguard Group Inc. (7.53%), Janus Henderson Group PLC (3.80%), Janus Henderson Group PLC (3.80%) and Brown Advisory Inc. (1.69%). Company insiders that own Integra Lifesciences stock include Barbara B Hill, Christian S Schade, Daniel L Reuvers, Glenn Coleman, Jeffrey Mosebrook, John Mooradian, Joseph Vinhais, Keith Bradley, Kenneth Burhop, Lisa Evoli, Peter J Arduini, Raymond G Murphy, Rhonda Germany Ballintyn, Richard D Gorelick, Richard E Caruso and Stuart Essig. View Institutional Ownership Trends for Integra Lifesciences.
Which institutional investors are selling Integra Lifesciences stock?
IART stock was sold by a variety of institutional investors in the last quarter, including Vaughan Nelson Investment Management L.P., Russell Investments Group Ltd., Natixis, Natixis, Man Group plc, Falcon Point Capital LLC, Bank of America Corp DE and D. E. Shaw & Co. Inc.. Company insiders that have sold Integra Lifesciences company stock in the last year include Christian S Schade, Daniel L Reuvers, Glenn Coleman, John Mooradian, Kenneth Burhop, Lisa Evoli, Peter J Arduini, Raymond G Murphy and Richard E Caruso. View Insider Buying and Selling for Integra Lifesciences.
Which institutional investors are buying Integra Lifesciences stock?
IART stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Janus Henderson Group PLC, Point72 Asset Management L.P., Marshall Wace LLP, First Trust Advisors LP, Landscape Capital Management L.L.C., Nuveen Asset Management LLC and Brown Advisory Inc.. Company insiders that have bought Integra Lifesciences stock in the last two years include Barbara B Hill and Rhonda Germany Ballintyn. View Insider Buying and Selling for Integra Lifesciences.
How do I buy shares of Integra Lifesciences?
Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Integra Lifesciences' stock price today?
One share of IART stock can currently be purchased for approximately $61.06.
How big of a company is Integra Lifesciences?
Integra Lifesciences has a market capitalization of $5.22 billion and generates $1.47 billion in revenue each year. The life sciences company earns $60.80 million in net income (profit) each year or $2.42 on an earnings per share basis. Integra Lifesciences employs 4,500 workers across the globe.View Additional Information About Integra Lifesciences.
What is Integra Lifesciences' official website?
How can I contact Integra Lifesciences?
Integra Lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]
MarketBeat Community Rating for Integra Lifesciences (NASDAQ IART)
MarketBeat's community ratings are surveys of what our community members think about Integra Lifesciences and other stocks. Vote "Outperform" if you believe IART will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IART will underperform the S&P 500 over the long term. You may vote once every thirty days.
